Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063852 · ClinicalTrials.gov registry record
PTNS on Urinary and Global Quality of Life in MS Patients
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 23
- Enrollment target
NCT04063852: Completed study, sponsored by University of Michigan.
NCT04063852 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04063852 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior treatment modalities who have elected to pursue PTNS therapy for LUTS.
Primary Outcome
Change from baseline in the median number of urinary frequency and/or urinary incontinence episodes on a 3 day voiding diary at 3, 12, and 24 months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2022-11-27 |
What the finished NCT04063852 record still lists
NCT04063852 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04063852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04063852 about?
NCT04063852 is a clinical study titled "PTNS on Urinary and Global Quality of Life in MS Patients". This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior treatment modalities who have elected to pursue PTNS therapy for LUTS.
What is the current status of trial NCT04063852?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2019-02-27. Estimated completion is 2022-11-27.
Who is sponsoring clinical trial NCT04063852?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI